Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries.

ABSTRACT:

Background

Bone metastases (BMs) are common in patients with breast cancer and can lead to skeletal-related events (SREs), which are associated with increased pain and reduced quality of life (QoL). Bone-targeted agents (BTAs), like zoledronic acid and denosumab, reduce the incidence of SREs and delay progression of bone pain.

Materials and methods

We evaluated the management of BMs and pain in six European countries (Belgium, France, Germany, Italy, Spain, and UK) using the Adelphi Breast Cancer Disease Specific Programme, which included a physician survey and patient-reported outcomes (PROs) to assess the impact of BMs on pain and QoL.

Results

301 physicians completed patient record forms for 2984 patients with advanced breast cancer; 1408 with BMs and 1136 with met

SUBMITTER: von Moos R 

PROVIDER: S-EPMC5993954 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature